Skingenix, Inc. announces treatment of the first patient with investigational drug, MW-III in adult patients with Second-Degree Thermal Burns in USA.

On 02 February 2023, in a Phase II, Open-Label, Randomized, Active-Controlled Pilot Study, the first patient was successfully treated with Skingenix’s investigational drug, MW-III by the investigator Jeffrey Shupp, MD, at MedStar Washington Hospital Center, in USA. This clinical study is currently ongoing, in which a total of 60 patients with Second-Degree Thermal Burns, will be enrolled and randomized to either investigational drug MW-III (30 patients) or active control (30 patients) Silvadene® Cream 1% (Silver Sulfadiazine). The study is currently recruiting eligible patients with Second-Degree Thermal Burns and is expected to be completed in 2023. For further details, please visit website (NCT01297400).